• Publications
  • Influence
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
BIIB015 is an immunoconjugate created for the treatment of solid tumours and is currently in Phase I of clinical evaluation. BIIB015 consists of a humanised monoclonal antibody against the CriptoExpand
  • 31
  • 2
CRIPTO3, a presumed pseudogene, is expressed in cancer.
Cripto is a cell surface protein highly expressed in certain solid tumors, and overexpression of Cripto protein is oncogenic. Cripto-1 protein is encoded by CRIPTO1 gene. CRIPTO3, a presumedExpand
  • 22
  • 1
Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model.
In a syngeneic murine model of multiple myeloma with many of the characteristics of the human disease, a monoclonal antibody (mAb) to the integrin very late antigen-4 (VLA-4), given after the myelomaExpand
  • 57
  • PDF
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Recent advances regarding the introduction of anti‐adhesion strategies as a novel therapeutic concept in oncology hold great promise. Here we evaluated the therapeutic potential of theExpand
  • 53